Diffusion Pharmaceuticals Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert J. Cobuzzi Jr.,
- Full Time Employees
- 13
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 300 East Main Street Charlottesville VA United States of America 22902
- IPO Date
- May 23, 2008
- CIK
- 0001053691
- Website
- diffusionpharma.com
- Similar Companies
- Business
- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) operates as a clinical-stage biotechnology company focused on developing therapies that enhance oxygen delivery to hypoxic tissues. The company offers trans sodium crocetinate (TSC), its lead product candidate, an oxygen diffusion-enhancing compound designed to improve tissue oxygenation in conditions such as glioblastoma multiforme (GBM), pancreatic cancer, brain metastases, peripheral artery disease, stroke, and other solid tumors; TSC has received orphan drug designation from the U.S. Food and Drug Administration for use as a radiosensitizer in newly diagnosed GBM patients. Diffusion Pharmaceuticals conducts clinical trials across these indications, including Phase 2 studies for GBM and investigations into COVID-19-related respiratory distress, with preclinical and early-stage work on related bipolar trans carotenoid salts for hemorrhagic shock, ischemia, and central nervous system disorders. Founded in 2001 and headquartered in Charlottesville, Virginia, the company targets patients with life-threatening hypoxic conditions, primarily in the United States and Eastern Europe through its clinical programs. In August 2023, Diffusion Pharmaceuticals completed a merger with EIP Pharma Inc., resulting in a reverse stock split, name change to CervoMed Inc., ticker symbol change to CRVO, and a strategic shift to focus on central nervous system disorders, including advancing neflamapimod for dementia with Lewy bodies while pausing further TSC development to pursue potential sales or out-licensing. The combined entity, now headquartered in Boston, Massachusetts, trades on Nasdaq under CRVO, with former EIP Pharma stakeholders owning the majority and the company prioritizing late-stage trials for neurodegenerative diseases. No significant updates to Diffusion's standalone operations or TSC pipeline have emerged since the merger as of late 2025.
CervoMed Announces Completion of Merger with EIP Pharma
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HSKA, LSI, EXR, DFFN
DIFFUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Diffusion Pharmaceuticals Inc. - DFFN
DFFN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Diffusion Pharmaceuticals Inc. Is Fair to Shareholders
Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
5 Stocks Halted In Tuesday's Session
Diffusion Pharmaceuticals (DFFN) Stock: 1-For-50 Reverse Stock Split Announced
Diffusion Pharmaceuticals' 50-For-1 Stock Split Will Go Into Effect Tomorrow
Why Diffusion Pharmaceuticals Shares Are Falling
Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during “J.P.
Diffusion Pharmaceuticals (DFFN) Stock: Why The Price Increased Today
Hot Biotech Penny Stocks to Watch As New Variant Creates Volatility
7 Biotech Penny Stocks With Huge Catalysts Coming in 2022
Diffusion Pharmaceuticals Issues Letter to Shareholders
Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment Conference
DFFN Stock: Over 7% Increase Pre-Market Explanation
Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA's Pulmonology, Allergy, and Critical Care Division
Diffusion Pharmaceuticals Reports Q2 Financial Results and Provides Business Update
Making a List of Penny Stocks to Buy? Here's 7 to Watch in Summer 2021